| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The primary targets of oxysanguinarine include malaria parasites, dengue virus, and platelet aggregation pathways. The compound has antimalarial activity. It has potential inhibitory properties against dengue virus. Oxysanguinarine possesses antiplatelet aggregation activity. The precise molecular targets and mechanisms of action require further elucidation.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated the biological activities of oxysanguinarine. The compound has antimalarial activity. It has potential inhibitory properties against dengue virus. Oxysanguinarine possesses antiplatelet aggregation activity. These activities support its potential for further investigation.
|
| ln Vivo |
In vivo activity of oxysanguinarine has been studied in the context of its antimalarial effects. The compound has been shown to have antimalarial activity. Specific in vivo data have been reported in the literature. Further studies are needed to fully characterize its in vivo efficacy.
|
| Enzyme Assay |
For antimalarial activity screening, standard in vitro assays using P. falciparum parasites are used. Parasites are cultured and treated with serial dilutions of oxysanguinarine. Parasite growth inhibition is assessed, and IC₅₀ values are calculated. For antiviral assays, dengue virus-infected cells are treated with the compound. For antiplatelet assays, platelet aggregation is measured.
|
| Cell Assay |
For in vitro cell-based studies, P. falciparum parasites are cultured in human erythrocytes and treated with serial dilutions of oxysanguinarine. Parasite growth is assessed, and IC₅₀ values are calculated. For antiviral studies, dengue virus-infected cells are treated with the compound. Viral replication is quantified.
|
| Animal Protocol |
In vivo animal studies for oxysanguinarine have been conducted in models of malaria. The compound has shown antimalarial activity. Standard protocols for in vivo efficacy studies are described in the literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of oxysanguinarine have not been extensively characterized. As an alkaloid with a molecular weight of 347.32 g/mol, it is expected to have reasonable membrane permeability. Specific PK parameters have not been reported.
|
| Toxicity/Toxicokinetics |
Toxicological data for oxysanguinarine are limited. As a natural alkaloid, it may have a favorable safety profile. However, systematic toxicological studies have not been extensively published. Safety assessments would be needed for therapeutic development.
|
| References |
[1]. Phurpa Wangchuk, et al. A new protoberberine alkaloid from Meconopsis simplicifolia (D. Don) Walpers with potent antimalarial activity against a multidrug resistant Plasmodium falciparum strain. J Ethnopharmacol. 2013 Dec 12;150(3):953-9.
|
| Additional Infomation |
Hydroxysanguinarine is a benzophenanthridine alkaloid. It has been reported in Pteris vittata, Corydalis yanhusuo, and other organisms for which relevant data are available.
Oxysanguinarine is a research compound used in studies of protoberberine alkaloids and their biological activities. It is isolated from Meconopsis simplicifolia. The compound has antimalarial, anti-dengue virus, and antiplatelet aggregation activities. No clinical trials or therapeutic applications have been reported. Oxysanguinarine serves as a research tool for studying alkaloid pharmacology, antimalarial mechanisms, and antiviral activity. |
| Molecular Formula |
C20H13NO5
|
|---|---|
| Molecular Weight |
347.3209
|
| Exact Mass |
347.079
|
| CAS # |
548-30-1
|
| PubChem CID |
443716
|
| Appearance |
White to off-white solid powder
|
| Density |
1.509±0.06 g/cm3(Predicted)
|
| Boiling Point |
628.7±55.0 °C(Predicted)
|
| Melting Point |
223-224 °C
|
| LogP |
3.302
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
26
|
| Complexity |
599
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C([H])([H])OC2C([H])=C([H])C3=C(C1=2)C(N(C([H])([H])[H])C1C2=C([H])C4=C(C([H])=C2C([H])=C([H])C=13)OC([H])([H])O4)=O
|
| InChi Key |
UFHGABBBZRPRJV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H13NO5/c1-21-18-12(3-2-10-6-15-16(7-13(10)18)25-8-24-15)11-4-5-14-19(26-9-23-14)17(11)20(21)22/h2-7H,8-9H2,1H3
|
| Chemical Name |
24-methyl-5,7,18,20-tetraoxa-24-azahexacyclo[11.11.0.02,10.04,8.014,22.017,21]tetracosa-1(13),2,4(8),9,11,14(22),15,17(21)-octaen-23-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8792 mL | 14.3959 mL | 28.7919 mL | |
| 5 mM | 0.5758 mL | 2.8792 mL | 5.7584 mL | |
| 10 mM | 0.2879 mL | 1.4396 mL | 2.8792 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
